Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Schizophrenia
Interventions
Emraclidine 15 mg, Emraclidine 30 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
Conditions
Schizophrenia
Interventions
RGH-188
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Conditions
Schizophrenia
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
39
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 30 more
Conditions
Agitation
Interventions
Asenapine, Placebo
Drug
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Schizophrenia
Interventions
bitopertin [RO4917838], olanzapine, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more
Conditions
Schizophrenia
Interventions
PF-00217830, Placebo, Aripiprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Psychosis, Anxiety, Depression, Behavioral and Psychiatric Symptoms of Dementia
Interventions
Behavioral Health Home Hospital
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Belmont, Massachusetts • Boston, Massachusetts • Jamaica Plain, Massachusetts
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions
BXCL501 Sublingual Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Chino, California • Oceanside, California • Orange, California + 2 more
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders, Anxiety Disorder
Interventions
Group Music Therapy Advocacy Recording Intervention (MTAR)
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Belle Mead, New Jersey
Conditions
Schizophrenia
Interventions
Cariprazine, Aripiprazole, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 17 more
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
Conditions
Schizophrenia
Interventions
Placebo, Brexpiprazole, Quetiapine extended release
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Escondido, California
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Conditions
Acute Schizophrenia
Interventions
OPC-34712, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
19
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 15 more
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Costa Mesa, California • Long Beach, California • Paramount, California + 12 more
Conditions
Schizophrenia
Interventions
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 29 more
Conditions
Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)
Interventions
Acute (24-hour) abstinence, Ad libitum smoking/vaping
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Schizophrenia
Interventions
OPC-34712, Placebo, Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 12 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Dexmedetomidine Hydrochloride, Placebos
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia
Interventions
TAK-063 20 mg, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more